KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Short term Debt (2016 - 2025)

Biogen has reported Short term Debt over the past 14 years, most recently at $150.0 million for Q2 2025.

  • For Q2 2025, Short term Debt changed N/A year-over-year to $150.0 million; the TTM value through Jun 2025 reached $150.0 million, changed N/A, while the annual FY2024 figure was $1.7 billion, 1065.73% up from the prior year.
  • Short term Debt for Q2 2025 was $150.0 million at Biogen, down from $1.7 billion in the prior quarter.
  • Over five years, Short term Debt peaked at $1.7 billion in Q4 2024 and troughed at $150.0 million in Q4 2023.
  • A 4-year average of $761.9 million and a median of $574.6 million in 2021 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 1065.73% in 2024 and fell as far as 1065.73% in 2024.
  • Year by year, Short term Debt stood at $999.1 million in 2021, then plummeted by 84.99% to $150.0 million in 2023, then soared by 1065.73% to $1.7 billion in 2024, then tumbled by 91.42% to $150.0 million in 2025.
  • Business Quant data shows Short term Debt for BIIB at $150.0 million in Q2 2025, $1.7 billion in Q4 2024, and $150.0 million in Q4 2023.